|Bid||665.00 x 0|
|Ask||690.00 x 0|
|Day's range||665.00 - 690.00|
|52-week range||116.00 - 690.00|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||N/A|
|Earnings date||21 Sep 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.03|
The big shareholder groups in MaxCyte, Inc. ( LON:MXCT ) have power over the company. Generally speaking, as a company...
When historians look back at 2020, it won’t be the coronavirus crisis that will claim their interest, but the award in October 2020 of the Nobel Prize in Chemistry to two female scientists for their work on the technology of genome editing. Their ‘CRISPR-Cas9’ discovery – which is also known as “genetic scissors” – enables […] The post Where I would invest for long-term exposure to disruptive cell-based medicines appeared first on The Motley Fool UK.
Doug Doerfler became the CEO of MaxCyte, Inc. (LON:MXCT) in 1999, and we think it's a good time to look at the...